Vanda Says Anxiety Drug Failed Late-Stage Study; Puts Program on Hold
Vanda Pharmaceuticals said its experimental social anxiety disorder drug failed the main goal of a late-stage study. The company put the program on hold pending further analysis of the data.
Vanda Pharmaceuticals (NASDAQ: VNDA) said Wednesday that its experimental treatment for social anxiety disorder did not meet the primary endpoint in a late-stage study. The company has paused the program while it conducts further analysis of the data. Shares of the biopharmaceutical company fell about 17% in exte…